Affordable Access

deepdyve-link
Publisher Website

[Prediction performances of 18F-FDG PET and CGFL/Curie nomogram after preoperative chemotherapy in Breast cancer].

Authors
  • Vincent, Laura1
  • Jankowski, Clémentine2
  • Arnould, Laurent3
  • Coudert, Bruno4
  • Rouzier, Roman5
  • Reyal, Fabien5
  • Humbert, Olivier6
  • Coutant, Charles7
  • 1 Département de Chirurgie Oncologique, Centre Georges François Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France. Electronic address: [email protected] , (France)
  • 2 Département de Chirurgie Oncologique, Centre Georges François Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France. , (France)
  • 3 Département de Biologie et Pathologie des tumeurs, Centre Georges François Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France. , (France)
  • 4 Département d'Oncologie Médicale, Centre Georges François Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France. , (France)
  • 5 Département de Chirurgie Oncologique, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. , (France)
  • 6 Département de Médecine Nucléaire, Centre Georges François Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France. , (France)
  • 7 Département de Chirurgie Oncologique, Centre Georges François Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France; ImVia, U.F.R Des Sciences de Santé, 7 boulevard Jeanne d'Arc, 21000 Dijon, France. , (France)
Type
Published Article
Journal
Gynecologie, obstetrique, fertilite & senologie
Publication Date
Mar 20, 2020
Identifiers
DOI: 10.1016/j.gofs.2020.03.015
PMID: 32205278
Source
Medline
Keywords
Language
French
License
Unknown

Abstract

Objectives The aim of this study was to compare the value of 18F-fluorodesoxyglucose positron emission tomography (18F-FDG PET/CT) with CGFL/Curie nomogram to predict a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in women with human epidermal growth factor 2 (HER2)-positive breast cancer treated by trastuzumab. Methods Fifty-one women with HER2-positive breast cancer treated with trastuzumab plus taxane-based NAC, were retrospectively included from January 2005 to December 2015. For 18F-FDG PET/CT, the analyzed predictor was the maximum standardized uptake value of the primary tumor and axillary nodes after the first course of NAC (PET2.SUVmax). pCR was defined by no residual infiltrative tumor but in situ tumor was accepted. Accuracy of CGFL/Curie nomogram and PET2.SUVmax was evaluated measuring sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV). Combined prediction was evaluated testing predictor's associations. Results For CGFL/Curie nomogram's performances, Se, Sp, PPV and NPV were respectively: 76% (CI95%: 58-90%), 57% (CI95%: 43-66%), 55% (CI95%: 42-65), 77% (CI95%: 59-90%). For PET2.SUVmax's performances, Se, Sp, PPV and NPV were respectively: 67% (CI95%: 48-81%), 77% (CI95%: 64-97%), 67% (CI95%: 48-82%), 77% (CI95%: 64-87%). ROC curves for these predictors were similar; the areas under the curve were 0.6 (CI95%: 0.56-0.64) for PET2.SUVmax and 0.55 (CI95%: 0.50-0.59) for CGFL/Curie nomogram. Combined prediction was efficient with Se at 80%, VPN at 76%, Sp at 78% and VPP at 81 %. Conclusions CGFL/Curie nomogram and PET2.SUVmax were two efficient predictors of pCR in patients with HER2-positive breast cancer. Combined prediction has an improved accuracy. Copyright © 2020. Published by Elsevier Masson SAS.

Report this publication

Statistics

Seen <100 times